ECE2020 Audio ePoster Presentations Hot topics (including COVID-19) (110 abstracts)
The role of growth hormone device optimisation in patient-reported outcomes: Real-world evidence from South Korea
Ji-Eun Lee 1 , Kee-Hyoung Lee 2 , Mi Jung Park 3 , Seung Yang 4 , Eun Young Kim 5 , Young-Jun Rhie 6 , Min-Ho Jung 7 , Aram Yang 8 , Shin-Hye Kim 3 , Lindsey Yoojin Chung 9 , Su Young Ko 5 , Young Ju Lee 10 , Navid Nedjatian 11 & Woo Yeong Chung 12
1Inha University Hospital, Incheon, Korea, Republic of South; 2Korea University Anam Hospital, Seoul, Korea, Republic of South; 3Inje University Sanggye Paik Hospital, Seoul, Korea, Republic of South; 4Hanyang University Guri Hospital, Guri, Korea, Republic of South; 5Chosun University Hospital, Gwangju, Korea, Republic of South; 6Korea University Ansan Hospital, Seoul, Korea, Republic of South; 7The Catholic University of Korea Yeouido St Mary’s Hospital, Seoul, Korea, Republic of South; 8Kangbuk Samsung Hospital, Seoul, Korea, Republic of South; 9Myongji Hospital, Hanyang University College of Medicine, Department of Pediatrics, Goyang, Korea, Republic of South; 10Novo Nordisk Pharma Korea Ltd, Medical Affairs, Seoul, Korea, Republic of South; 11Novo Nordisk Health Care AG, Global Medical Affairs, Zurich, Switzerland; 12Inje University Busan Paik Hospital, Busan, Korea, Republic of South
Growth hormone (GH) therapy (GHT) requires long-term commitment to daily sc GH injections that may present adherence challenges. Patient preference and adherence have been shown to be affected by delivery devices in association with convenience of administration, level of injection-site pain, confidence in correct dose administration and satisfaction with the device. This survey investigated if switching GH device – from NordiLet/others to NordiFlex – improved patient-reported preference, satisfaction, ease of use and adherence in paediatric patients receiving GHT in South Korea. Patients aged 4 to ≤ 18 years receiving GHT from paediatric clinics in South Korea between January and July 2019 were surveyed. Participants were current users of NordiFlex for 4–24 weeks who had previously used NordiLet or other GH devices for ≥ 12 weeks before switching. Patients/caregivers compared the subjective benefits of NordiFlex vs previous device in a 25-question survey comprising four domains: ease of use, self-efficacy, minimal disruption of daily life, feelings about injections. Patients responded on a 5-point Likert scale (−2 strongly disagree, −1 disagree, 0 no difference, 1 agree, 2 strongly agree). The survey also included questions about preference for, as well as satisfaction, perceived ease of use and self-reported adherence with, NordiFlex vs previous device. 94 patients were included in the survey. 91.5% previously used NordiLet; the rest used another device. Only 8.5% self-administered GH. A significantly greater proportion of patients preferred, and were more satisfied with, NordiFlex vs previous device; mean score: 0.65 (95% CI : 0.41; 0.88) and 0.61 (95% CI : 0.36; 0.85), respectively. Similarly, patients reported greater perceived ease of use and fewer missed injections with NordiFlex vs previous device; mean score: 0.49 (95% CI : 0.26; 0.72) and 0.20 (95% CI : 0.06;0.34), respectively. Bivariate analyses showed significant associations between the four domains and preference, satisfaction, perceived ease of use and self-reported adherence for NordiFlex vs previous device (P ≤ 0.005). After multivariate analyses, higher scores of ease of use (adjusted OR [95% CI]: 3.77 [1.04; 13.57]; P = 0.042) and minimal disruption of daily life (adjusted OR [95% CI]: 5.05 [1.09; 23.25]; P = 0.038) were still significantly associated with preference for NordiFlex. However, associations with self-efficacy (adjusted odds ratio 1.10 [95% CI : 0.38; 3.21]) and feelings about injection (adjusted odds ratio 1.63 [95% CI : 0.44–6.01]) were no longer statistically significant (P > 0.05). Patients reported greater preference, satisfaction, perceived ease of use and self-reported adherence with NordiFlex vs previous device, suggesting that improvements in injection device features could be associated with improved patient treatment experiences.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more